BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Timberlyne Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Timberlyne Therapeutics's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06830395-3258@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lumrotatug: Phase 2 readout est. (NCT06830395)
DESCRIPTION:Lumrotatug\, phase 2.\nStudy: Study of CM313 in Subject With Ig
 A Nephropathy\nEstimated primary completion: March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/lumrotatug#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06830395
URL:https://assetmemo.bio/drug/lumrotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792019-3258@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Lumrotatug: Phase 1/2 readout est. (NCT06792019)
DESCRIPTION:Lumrotatug\, phase 1/2.\nStudy: Study of CM313(SC) Injection in
  Subjects With Platelet Transfusion Refractoriness\nEstimated primary comp
 letion: 16 November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lumrotatug#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06792019
URL:https://assetmemo.bio/drug/lumrotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06791824-3258@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lumrotatug: Phase 1/2 readout est. (NCT06791824)
DESCRIPTION:Lumrotatug\, phase 1/2.\nStudy: Study of CM313(SC) Injection in
  Subjects With Relapsed/Refractory Aplastic Anemia\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/lumrotatug#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06791824
URL:https://assetmemo.bio/drug/lumrotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910903-3258@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Lumrotatug: Phase 3 readout est. (NCT07910903)
DESCRIPTION:Lumrotatug\, phase 3\, Multiple Myeloma.\nStudy: Study of CM336
 +CM313 Combination Therapy in Patients With Relapsed or Refractory Multipl
 e Myeloma\nEstimated primary completion: May 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lumrotatug#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07910903
URL:https://assetmemo.bio/drug/lumrotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
